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related hospitalization and patient follow-up was calculated based on data from
statistics of the Hospital Remuneration System, the G-DRG hospital payment
scheme and the office-based doctors’ fee scale. The cost caused due to recovery and
disability was estimated based on information from the Federal Statistical Office
and data of the Federal Health Reporting. Experts were interviewed to provide
follow-up resource use information. RESULTS: A total of 78,229 hospitalized leio-
myoma-related cases were treated in year 2009. 80% were hysterectomies, 14%
myomectomies and 6% were related to other therapies. Concerning the therapy
cost per patient, hysterectomy reveals the highest therapy cost, (€5913) followed by
myomectomy (€5793), UAE (€4675) and MR-HIFU (€4311). In a scenario without MR-
HIFU the cost per case accrued to a total of €5840. The budget impact analyse
targeting a patient group between 30 and 45 years of age, reveals a potential cost-
benefit of €1529 per patient if MR-HIFU would be introduced in the SHI system.
CONCLUSIONS: Our results suggest that MR-HIFU due to the administration in the
outpatient sector, the low complication rate and the low disability cost should be
considered as a cost-favourable alternative for the therapy of uterine fibroids.
PSU11
MEDICO-ECONOMIC ANALYSIS OF THE IMPACT OF MALNUTRITION ON THE
POST-OPERATIVE COURSE OF COLORECTAL CANCER PATIENTS
Preaud E1, Melchior JC2, Carles J3, Brami M4, Duru G5, Fontaine E6, Hébuterne X7,
Lukacs B8, Zazzo JF9, Panis Y10, Nitenberg G11
1Mapi Values, Lyon, France, 2R. Poincaré Hospital, APHP, Garches, France, 3JNB-Développement,
Paris, France, 4Technical Agency for Information about Hospitalization, Paris, France, 5Cyklad
Group, Rilleux la Pape, France, 6University Hospital Center, Grenoble, France, 7University
Hospital Center, Nice, France, 8Tenon Hospital, APHP, Paris, France, 9Antoine-Béclère Hospital,
APHP, CLAMART , France, 10Beaujon Hospital, APHP, Clichy, France, Paris 11University, Paris,
France
OBJECTIVES: The aim of this study was to assess the clinical and economic impact
of malnutrition in post-surgery colorectal cancer patients. METHODS: We per-
formed post-hoc analyses of the data collected in the Alves and al* prospective
study. The following criteria for malnutrition were used: weight loss10% in the 6
months pre-surgery and/or BMI18.5 (pts 70 years) or 21 (pts 70 years). 2
groups (gps) were created a posteriori: Well-Nourished (WN) and Malnourished
(MN) pts. Postoperative morbidity, mortality, hospital length-of-stay (LOS), and
hospital discharge setting were compared between the 2 gps. Individual costs were
valued using the French National Cost Study. We defined 3 scenarios: the most
accurate estimate and the upper and lower possible limits of this estimate. The
economic impact of malnutrition was assessed by calculating the difference in cost
per hospital stay between MN and WN pts. RESULTS: A total of 762 pts were in-
cluded in the analyses. Gps had the same characteristics, except more MN pts
underwent emergent surgery. Complication rate was not significantly different
between the 2 gps; mortality was higher in MN pts (7.4% vs. 4.1%, p0.056) and MN
pts had a mean LOS 3.1 days longer than WN pts (p0.004). A greater proportion of
MN pts could not be discharged and were referred to another facility (69.6% vs.
54.2%, p0.027). Malnutrition impacts the cost per hospital stay by about 3154€ per
patient (most accurate estimate), creating an annual impact of 9,572,770€ for
French public hospitals. CONCLUSIONS: Malnutrition in colorectal cancer surgical
pts is associated with a significant increase of LOS and delays returning home
following hospitalization; both have significant budget impact. Prospective studies
are needed to further investigate this impact and related cost-benefit of (special-
ized) nutritional support in this homogeneous category of patients.
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OBJECTIVES: To examine real world health care utilization (HCU) and costs asso-
ciated with whole brain radiation therapy (WBRT) or stereotactic radiosurgery (SRS)
as the initial or only treatment of brain metastasis (BrMets). METHODS: A retro-
spective longitudinal analysis utilized claims data from a national health insurer,
identifying patients18 yrs with2 claims7 days apart for BrMets (ICD-9 198.3x)
from 1/2004-4/2010. The index date was first BrMts claim date. Pre-index period of
6 months and 1 month post-index enrollment (1 month was permitted if due
to death). Patients with primary brain cancers were excluded. HCU and all-cause
per-patient per-month (PPPM) costs were examined. RESULTS: The study included
1,901 and 303 patients who received WBRT or SRS as first or only treatment, with
179d vs. 306d follow-up, respectively. Baseline Charlson comorbidity scores were
similar. Mean age at BrMets diagnosis was higher for WBRT (59yrs) vs. SRS (57yr)
[p-value0.002]. Rates of HCU (events/person-month) were higher among WBRT
vs. SRS patients for office visits (5.29 vs. 3.69), ER visits (0.25 vs. 0.17), and inpatient
stays (0.26 vs. 0.17); rates of outpatient visits were lower among WBRT patients
(2.31 vs. 3.24) [p-value0.001]. Total costs PPPM were higher for the SRS ($20,682) vs.
WBRT cohort ($16,909) [p-value0.005]. Outpatient costs PPPM was the major cost-
driver among the SRS cohort ($8,936, 43% of total) vs. $3,192 (19% of total) for WBRT.
Office costs PPPM contributed most to overall cost among WBRT ($3,428, 20% of
total) vs. $3,053 (18% of total) for SRS. Pharmacy costs PPPM were higher for the SRS
($1,232) vs. WBRT cohort ($692) [p-value 0.001]. CONCLUSIONS: BrMets patients
with SRS incurred higher cost compared to WBRT patients. SRS is recommended
for BrMets patients with 3 lesions and WBRT in 3 lesions may explain longer
survival among SRS patients. Additional studies are augmented to understand
differences.
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OBJECTIVES: To estimate the healthcare resource utilization and their associated
costs secondary to fasciectomy of Dupuytren=s disease treated according with
usual medical practice in public hospital centers in Spain. METHODS: This multi-
center, observational, retrospective cohort study, extracted data through the revi-
sion of medical records of three tertiary public hospitals. Each center should recruit
40 patients which were operated for Dupuytren=s disease, as principal diagnose of
Minimum Data Set, in which the surgical procedure conducted was fasciectomy,
during 2007-2009. To collect all the resources consumed during surgery, a health-
care resource utilization form was designed. Demographic (age, gender, occupa-
tional status), clinical (time of evolution of the pathology and comorbilities) and
healthcare utilization (hospitalizations, medical visits, test, and drugs) data were
collected under medical routine. Unitary costs were provided by e-SALUD and BOT
data base. RESULTS:A total of 123 subjects (86.2% men; 35.8% active workers) were
identified. 17.8% of subjects were diagnose of Dupuytren before year 2000; 8.4%
between 2000-2005 and 73.8% after 2006. 81.3% of patients had at least one comor-
bidity, being hypertension (45%) the most frequent. 71.6% of patients were hospi-
talized in orthopedist (75%) and plastic surgery unit. Mean(SD) length of hospital
stay was 1.5(1.1) days. 28.4% there were operated in ambulatory surgery. All the
patients had follow-up visits after surgery, 27% needed physical therapy, 88% per-
formed preoperative tests and 8% visit the emergency room after surgery. Health-
care mean costs were as follows: fasciectomy €1074(0); hospitalizations €978(743);
ambulatory €186(10); follow-up visits €260(173); emergency rooms €13(53); tests
€132(121); drugs €7(9); physical therapy €46(134). Total cost for patients with Du-
puytren’s disease treated with surgery was €2304(825). There were no significant
differences between the three centers analyzed; p0.181. CONCLUSIONS: This
evaluation suggest that healthcare resources utilization for surgical treatment for
patients with Dupuytren’s disease may cost €2,304(825) per surgery (fasciectomy)
treated under usual medical practice in Spain.
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OBJECTIVES: To examine changes in post-tubal ligation complications and their
associated costs over time.METHODS:Data were obtained from the US i3 Invision™
Data Mart. Data collected spanned the period from January, 2006 through March,
2010. CPT and ICD-9 codes were used to identify patients who received a tubal
ligation as well as a post-tubal ligation complication. Patients were also subcate-
gorized based upon year of tubal ligation (2007, 2008, or 2009) in order to examine if
there were any noticeable trends over time. RESULTS: There were 15,169 women
under age 50 who received a tubal ligation and had continuous insurance coverage
in the 1 year post-tubal ligation. The mean age at tubal ligation was 35.26 years
(SD5.46) with 10.46% having tubal ligation at the time of a pregnancy. Overall,
21.68% (n3,288) of women experienced at least 1 complication, with the most
common being heavy menstrual bleeding (n2,190, 14.44%) and surgical compli-
cations (n729, 4.81%). When assessing changes in complications from 2007-2009,
diagnoses of heavy menstrual bleeding (p0.0003), sepsis (p0.0392), surgical com-
plications (p0.0240), and any complication (p0.0001) all showed statistically sig-
nificant increases over time. Of all women who had a tubal ligation, charges asso-
ciated with the tubal ligation did not increase significantly from 2007-2009;
however, the charge associated with complications did show a statistically signif-
icant increase over the same time period. The average charge for women who
experienced a complication (n3,228) was $37,425 (SD$68,249). CONCLUSIONS:A
substantial number of women experience post-tubal ligation complications and
the charges associated with these complications have increased significantly over
time.
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OBJECTIVES: There are limited data currently available regarding the prevalence of
post-transplant events and associated resource utilization in renal transplant pa-
tients in clinical practice. This study aims to describe the healthcare resource
utilization and costs of managing patients after renal transplantation, stratified by
relative graft functioning status, using observational data from relevant databases
and physician questionnaires from transplant centres across Europe. METHODS:
Data from renal databases in Cardiff and Leuven University Hospitals have been
analysed to assess 3-year post-transplant resource use in the UK and Belgium,
respectively. Similar data have been derived from questionnaires administered in
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